A second meta-analysis of clinical studies with resveratrol in T2D patients (nine randomized controlled trials with 283 subjects) reported that resveratrol could significantly reduce levels of FBS with concomitant beneficial effects on HOMA-IR scores and levels of insulin [42]. This evidence concerns the gene INS and type 2 diabetes mellitus.